Postoperative tegafur-uracil for stage I lung adenocarcinoma: first real-world data with an exploratory subgroup analysis.
Postoperative adjuvant therapy
Stage I lung adenocarcinoma
Tegafur–uracil
Visceral pleural invasion
Journal
Surgery today
ISSN: 1436-2813
Titre abrégé: Surg Today
Pays: Japan
ID NLM: 9204360
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
15
03
2022
accepted:
12
05
2022
pubmed:
3
7
2022
medline:
11
1
2023
entrez:
2
7
2022
Statut:
ppublish
Résumé
The effect of postoperative tegafur-uracil on overall survival (OS) after resection of stage I adenocarcinoma has been shown in clinical trials. The purpose of this study was to investigate whether findings from randomized trials of adjuvant tegafur-uracil are reproducible in a real-world setting. A retrospective cohort study was performed using a multi-institutional database that included all patients who underwent complete resection of pathological stage I adenocarcinoma between 2014 and 2016. Survival outcomes for patients managed with and without tegafur-uracil were analyzed using the Kaplan-Meier method and a Cox proportional hazards model for the whole patient cohort and in a selected cohort based on eligibility criteria of a previous randomized trial. Propensity score matching was used to adjust for confounding effects. After propensity score matching, the hazard ratios for OS were 0.57 (95% confidence interval (CI) 0.29-1.14, P = 0.11) in the whole cohort and 0.69 (95% CI 0.32-1.50, P = 0.35) in the selected cohort. The effects of tegafur-uracil in this retrospective study appear to be consistent with those found in randomized clinical trials. These effects may be maximized in patients aged from 45 to 75 years.
Identifiants
pubmed: 35780275
doi: 10.1007/s00595-022-02546-z
pii: 10.1007/s00595-022-02546-z
doi:
Substances chimiques
Tegafur
1548R74NSZ
Uracil
56HH86ZVCT
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
135-144Informations de copyright
© 2022. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.
Références
Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2010;28(1):29–34.
doi: 10.1200/JCO.2009.24.0333
Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzales-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):719–27.
doi: 10.1016/S1470-2045(06)70804-X
Felip E, Altorki N, Zhou C, Csőszi T, Vynnychenko I, Goloborodko O, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344–57.
doi: 10.1016/S0140-6736(21)02098-5
NCCN clinical practice guidelines in Oncology. Non-Small Cell Lung Cancer, Available at NCCN, https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf Accessed Dec 28, 2020.
Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–iv21.
JLCS clinical practice guidelines in Non-Small Cell Lung Cancer, Available at JLCS, https://www.haigan.gr.jp/guideline/2019/1/2/190102040100.html#cq27 Accessed Sep 11, 2020.
Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350(17):1713–21.
doi: 10.1056/NEJMoa032792
Hamada C, Tsuboi M, Ohta M, Fujimura S, Kodama K, Imaizumi M, et al. Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials. J Thorac Oncol. 2009;4(12):1511–6.
doi: 10.1097/JTO.0b013e3181bbf1f2
Chen YY, Huang TW. Prognostic factors of patients with pathologic stage I lung adenocarcinoma. J Thorac Dis. 2018;10(Suppl 9):S1115–8.
doi: 10.21037/jtd.2018.04.37
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85.
doi: 10.1097/JTO.0b013e318206a221
Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315–6.
doi: 10.1097/JTO.0b013e3181ec173d
Kunitoh H, Tsuboi M, Ohta M, Wakabayashi M, Okada M, Suzuki K, et al. A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non–small cell lung cancer (JCOG 0707). JTCVS Open. 2020;4:90–102.
doi: 10.1016/j.xjon.2020.08.009
Soh J, Toyooka S, Okumura N, Nakamura H, Nakata M, Yamashita M, et al. Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil-tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial. Int J Clin Oncol. 2019;24(11):1367–76.
doi: 10.1007/s10147-019-01508-9
Toyooka S, Okumura N, Nakamura H, Nakata M, Yamashita M, Tada H, et al. A multicenter randomized controlled study of paclitaxel plus carboplatin versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer. J Thorac Oncol. 2018;13(5):699–706.
doi: 10.1016/j.jtho.2018.02.015
Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399(10335):1607–17.
doi: 10.1016/S0140-6736(21)02333-3
Kato T, Ishikawa K, Aragaki M, Sato M, Okamoto K, Ishibashi T, et al. Angiolymphatic invasion exerts a strong impact on surgical outcomes for stage I lung adenocarcinoma, but not non-adenocarcinoma. Lung Cancer. 2012;77(2):394–400.
doi: 10.1016/j.lungcan.2012.04.002
Kaseda K, Ishii G, Aokage K, Takahashi A, Kuwata T, Hishida T, et al. Identification of intravascular tumor microenvironment features predicting the recurrence of pathological stage I lung adenocarcinoma. Cancer Sci. 2013;104(9):1262–9.
doi: 10.1111/cas.12219
Leeman JE, Rimner A, Montecalvo J, Hsu M, Zhang Z, von Reibnitz D, et al. Histologic subtype in core lung biopsies of early-stage lung adenocarcinoma is a prognostic factor for treatment response and failure patterns after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2017;97(1):138–45.
doi: 10.1016/j.ijrobp.2016.09.037
Yang Y, Mao Y, Yang L, He J, Gao S, Mu J, et al. Prognostic factors in curatively resected pathological stage I lung adenocarcinoma. J Thorac Dis. 2017;9(12):5267–77.
doi: 10.21037/jtd.2017.11.65
Funai K, Sugimura H, Morita T, Shundo Y, Shimizu K, Shiiya N. Lymphatic vessel invasion is a significant prognostic indicator in stage IA lung adenocarcinoma. Ann Surg Oncol. 2011;18(10):2968–72.
doi: 10.1245/s10434-011-1729-9
Mizuno T, Ishii G, Nagai K, Yoshida J, Nishimura M, Mochizuki T, et al. Identification of a low risk subgroup of stage IB lung adenocarcinoma patients. Lung Cancer. 2008;62(3):302–8.
doi: 10.1016/j.lungcan.2008.03.032
Ryu JS, Choi CM, Yang SC, Song SY, Jeon YJ, Jang TW, et al. Prognostic effect of age on survival of patients with stage I adenocarcinoma of the lung. Tumori. 2012;98(1):99–104.
doi: 10.1177/030089161209800114
Hattori A, Matsunaga T, Takamochi K, Oh S, Suzuki K. Prognostic impact of a ground glass opacity component in the clinical T classification of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2017;154(6):2102–10 e1.